Patients underestimate risk of deep vein thrombosis, say researchers

September 3, 2012

(Medical Xpress)—Many people going into hospital have concerns about contracting the hospital acquired infection MRSA, yet the risk of acquiring - and dying from – hospital acquired venous thromboembolism (VTE) is much greater, warn scientists at the University of Birmingham.

Hospital acquired VTE kills more people than , , HIV/AIDS and MRSA combined, report scientists from the University's School of Health and Population Sciences who are carrying out the ExPeKT study into how best to prevent and manage thromboembolism.

"Poor public knowledge of VTE, which is largely confined to blood-clots associated with air travel, is not surprising when the risk is also underestimated by hospitals, who continue in failing to provide appropriate clot-preventing drugs," says Dr Lorraine McFarland, who is leading the research. What is even more surprising, she says, is the lack of appreciation of these risks among .

VTE includes (DVT) and (PE), and risk factors include; , acute illness, major and orthopaedic surgery, malignancy, pregnancy, increasing age and obesity. A combination of these factors further increases the risk. Since the publication of clinical guidelines and recommendations by the National Institute for Health and Clinical Excellence (NICE) in 2007, all patients admitted to hospital in the UK should undergo a routine VTE .

The correct and uniform implementation of these guidelines across the UK is essential, says Dr McFarland.

"VTE is difficult to diagnose, often asymptomatic; the first sign of the disease can be a sudden fatal PE, and a lack of routine post-mortem examinations means it can remain unrecognised even at death,' she says. 'These factors suggest there may be a marked underestimate of VTE incidence. However, VTE is largely preventable. Routine risk assessment on hospital admission and the use of effective preventive strategies such as compression stockings and small doses of anticoagulants, including low molecular weight heparin (LMWH), can reduce the 32,000 deaths that occur each year from this condition and relieve the long-term debilitating burden created when veins become damaged by DVT."

The risk of VTE is greatest within the first 90 days after leaving hospital and remains high for up to 12 months. A VTE occurring within 90 days of a hospital discharge is classified as a hospital-acquired VTE. Primary healthcare professionals have little involvement in VTE aftercare and patients may self-administer thromboprophylaxis for up to 35 days. 'Primary healthcare professionals often remain unaware if a patient experiences a VTE event or is re-admitted to hospital and thus a period of clinical void exists for the patient.

"The importance of the ExPeKT study is in examining and defining the role of primary care in thromboprophylaxis and in exploring the information and care that high-risk patients receive prior to or after discharge," adds Dr McFarland. 'The outcome will be to develop a pathway for the co-ordinated care and the integrated management of thromboprophylaxis between hospital and the community; in effect bridging the void for patient care.

"The need for awareness and education across both secondary and primary care is evident. An informed patient requires understanding and knowledge of the VTE risks associated with hospitalisation, medical procedures and immobilisation in order to know which questions to ask when admitted to hospital."

"An effective intervention would educate a patient to recognise the symptoms of DVT and PE and instil the confidence to know who to approach if they suspect they are experiencing an event. Primary care could play a major role in this task, which will inevitably reduce the numbers of patients with -acquired VTE and prevent large numbers of unnecessary deaths."

Explore further: In colorectal surgery, risk for blood clots appears higher with open method versus laparoscopy

Related Stories

Venous thromboembolism up in adult hospitalizations

June 8, 2012

(HealthDay) -- Every year, more than half a million hospitalized U.S. adults acquire venous thromboembolism (VTE), a growing public health concern that is often preventable, according to research published in the June 8 issue ...

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

Arthritis drug may help with type of hair loss

September 22, 2016

(HealthDay)—For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.